Silexion Therapeutics Corp

What they do

Silexion conducts operations through its subsidiary, Silexion Israel, and is developing SIL204, a second-generation siRNA designed to silence the KRAS oncogene in cancers such as pancreatic, colorectal, and lung. The company uses an Integrated Treatment Regimen that combines direct tumor injection and subcutaneous systemic delivery of SIL204 with standard-of-care chemotherapy. It has not generated any revenues, relying on financing and grants to fund clinical development.

Revenue drivers

• No commercial products — The company has no approved products or revenue streams; all operations are clinical-stage and pre-revenue.
• SIL204 (lead candidate) — SIL204 is the primary asset, a second-generation siRNA targeting KRAS mutations; potential revenue dependent on successful clinical trials and regulatory approval.
• Grants from Israeli Innovation Authority (IIA) — Received $5.8 million in IIA grants through March 31, 2026, all prior to the Business Combination, providing non-dilutive funding but with royalty-bearing obligations.

Recent performance

Net loss widened from $5.1M in 2023 to $16.5M in 2024, then narrowed to $11.9M in 2025. Operating cash flow was negative each year, at -$4.5M (2023), -$8.4M (2024), and -$10.8M (2025). As of March 31, 2026, the company held $2.4M in cash and equivalents with total assets of $4.6M and shareholders' equity of just $291,000. Diluted EPS figures were unusual due to share count changes: $659.55 (2023), $3955.11 (2024), and $89.61 (2025). The company has not recorded any revenues.

Strategy

Management is advancing SIL204 toward clinical studies, with initiation expected in Q2 2026 pending regulatory clearance. They have onboarded external vendors to support operational readiness. The approach differentiates by silencing the KRAS oncogene rather than inhibiting downstream signaling. Financing has been raised via PIPE ($2.0M at Business Combination) and an equity line of credit (ELOC, up to $15M, with $3.1M drawn prior to 2025). The company also plans to wind down Moringa, a non-operational subsidiary.

Risks

• Cash runway — Only $2.4M cash as of March 31, 2026, against ongoing negative operating cash flow (~$10.8M in 2025), raising substantial doubt about ability to fund operations.
• Clinical-stage uncertainty — SIL204 has not received regulatory approval; Phase 2 data from first-generation siRNA may not predict SIL204's success.
• Regulatory clearance — Initiation of clinical studies is contingent on obtaining regulatory clearance, which may be delayed or denied.
• Dilution and share structure — Future financing through the ELOC or other offerings could dilute existing shareholders, and the company's low stock price and reverse split history indicate volatility.

Outlook

The company expects to initiate clinical studies for SIL204 in the second quarter of 2026, pending regulatory clearance. Management plans to continue developing the Integrated Treatment Regimen combining SIL204 with chemotherapy. However, given the limited cash position, the company will likely need to raise additional capital in the near term to sustain operations and meet its milestones.